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Abstract
Aim: Our aim was to update the recommendations for the diagnosis, treatment and 
follow‐up of the first febrile urinary tract infection in young children, which were 
endorsed in 2012 by the Italian Society of Pediatric Nephrology.
Methods: The Italian recommendations were revised on the basis of a review of 
the literature published from 2012 to October 2018. We also carried out an ad hoc 
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1  | INTRODUC TION
In this paper, we present the updated recommendations for the diag‐
nosis, treatment and follow‐up of the first febrile urinary tract infec‐
tion (UTI) in young children, endorsed by the Italian Society of Pediatric 
Nephrology and the Italian Society for Pediatric Infectivology. Our 
previous document 1 has been revised 6 years after its publication, on 
the basis of recently published literature and the results of an ad hoc 
evaluation of the risk factors previously proposed to guide clinicians 
in the identification of children with high‐grade vesicoureteral reflux 
(VUR).2 As regards risk factors, only the presence of a pathogen other 
than Escherichia coli significantly predicted high‐grade reflux both in 
the univariate (odds ratio 2.52, 95% Confidence Interval 1.32‐4.81, 
P < .005) and multivariate analyses (odds ratio 2.74, 95% CI: 1.39‐5.41, 
P = .003). The other three most frequent risk factors, abnormal renal 
and bladder ultrasound (RBUS), abnormal prenatal ultrasound, male 
younger than 6 months at UTI occurrence, were neither significantly 
nor independently associated with the presence of high‐grade reflux.2
As in the previous version, these recommendations apply to in‐
fants and young children, 2 months to 3 years of age, with a first 
febrile UTI, based on a temperature of at least 38°C. We excluded 
infants younger than 2 months of age, because of their specific fea‐
tures and specific treatment needs and children older than 3 years 
of age because of the lower risk of nephro‐urologic abnormalities 
and different clinical presentation. Children with immunodeficiency, 
a previous workup for congenital malformation of the kidney or uri‐
nary tract, or those requiring admission to an intensive care unit 
were also excluded. The updated recommendations follow the same 
structure as previously, considering 4 major topics: diagnosis, treat‐
ment, imaging and antibiotic prophylaxis and grading the evidence 
on the basis of the SORT criteria: strong (grade A), moderate (grade 
B) or weak (grade C) in support of a particular intervention.3
The recommendations are intended for use by all physicians deal‐
ing with febrile infants and children inside and outside the hospital 
and by specialists in paediatric and adult nephrology and urology.
2  | DIAGNOSIS
2.1 | When to suspect a UTI
A diagnosis of UTI should be considered in children presenting with 
fever of 38°C or higher,4 with no apparent source (grade A).5 In chil‐
dren aged 2 to 3 months, fever may be absent and clinical manifesta‐
tions may include lethargy, irritability and vomiting.6 The absence 
of fever in the first 3 months of life does not correlate with a less 
severe condition,6 and the risk of complications, such as sepsis and 
meningitis, at this age is greater.7 In older children, frequency, dysu‐
ria and changes in continence habits may be early symptoms, while 
abdominal pain and loin tenderness can be associated with fever. 
Key notes
• We updated the 2012 Italian recommendations for the 
first febrile urinary tract infection in young children and 
introduced four major modifications.
• The method for collecting urine for culture and its in‐
terpretation has been re‐evaluated, and we have refor‐
mulated the algorithm that guides clinical decisions to 
proceed with voiding cystourethrography.
• The suggested antibiotics have been revised and we 
have recommended further restrictions of the use of 
antibiotic prophylaxis.
evaluation of the risk factors to identify children with high‐grade vesicoureteral reflux 
or renal scarring, which were published in the previous recommendations. When evi‐
dence was not available, the working group held extensive discussions, during various 
meetings and through email exchanges.
Results: Four major modifications have been introduced. The method for collecting 
urine for culture and its interpretation has been re‐evaluated. We have reformulated 
the algorithm that guides clinical decisions to proceed with voiding cystourethrogra‐
phy. The suggested antibiotics have been revised, and we have recommended further 
restrictions of the use of antibiotic prophylaxis.
Conclusion: These updated recommendations have now been endorsed by the Italian 
Society of Pediatric Nephrology and the Italian Society for Pediatric Infectivology. 
They can also be used to compare other recommendations that are available, as a 
worldwide consensus in this area is still lacking.
K E Y W O R D S
antibiotic treatment, children, febrile urinary tract infection, prophylaxis, vesicoureteral reflux
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The presence of malodorous urine is neither specific nor sensitive 
enough to help in the diagnosis of febrile UTI (grade B).8 Poor growth 
has also been reported as a possible sign of UTI, but in our opinion 
poor growth is mainly related to recurrent infections or to associated 
conditions such as chronic kidney disease.
2.2 | What to do when a UTI is suspected
Urine should be collected and analysed by dipstick or microscopy to 
identify children in whom UTI is very likely,9 and, if urinalysis is ab‐
normal, by urine culture (UC) to obtain a definitive diagnosis5 (grade 
A). The presence of leucocyturia and bacteriuria in a fresh urine 
specimen and/or positivity for leucocyte esterase (LE) at dipstick 
suggests a diagnosis of UTI in symptomatic children. Urine culture 
can confirm the diagnosis based on the growth of a single bacterial 
strain.5,10 The interpretation of urine dipstick which is positive for 
nitrites and negative for leucocytes is not simple, as infection stimu‐
lates an inflammatory response in the host, represented in UTI by 
the presence of urinary leucocytes. Therefore, the positivity of urine 
culture in the absence of leucocyturia has to be evaluated with cau‐
tion, as it could represent bacteriuria and not UTI. If fever persists 
we recommend to repeat dipstick to check for the appearance of 
leucocyturia.
2.3 | How to collect urine
Collecting urine in small children represents a hard practical task. 
Four methods of urine collection are utilised, with no agreement in 
the literature: urinary bag, clean voided urine (CVU), transurethral 
bladder catheterisation (BC) and suprapubic aspiration (SPA). Each 
method has to be performed following standardised procedures.11‐18 
As regards dipstick and urinalysis implementation, any method for 
urine collection is feasible (grade A).5,11,12,19‐22
How to collect urine for UC has been extensively analysed by 
the NICE Working Group4 and by Whiting et al23 and is summarised 
in Table 1. Suprapubic aspiration and transurethral BC are the least 
likely to yield a contaminated growth (grade A). These methods are 
cumbersome to implement in primary care as a routine procedure, 
but feasible in hospital settings.5,11,19 In particular, SPA should be 
recommended in some circumstances, such as severe phimosis, 
vulvar synechia, infections or malformations of the external geni‐
talia.20 The use of CVU as an alternative to invasive methods is 
controversial 20,21; it is recommended by the Australian and English 
guidelines,4,11,23 while the American Academy of Pediatrics does not 
consider it a valid method for UC.5 When CVU is used in infants, 
a simple, quick and effective method to stimulate micturition has 
been reported, though contamination has not been evaluated.14‐18 
The use of a bag to collect a UC sample is only recommended by our 
previous guidelines1 and the 2018 NICE guidelines 4; in the recent 
literature, most authors recommend its use only in order to perform 
dipstick analysis.5,11,12,19‐22
On the basis of these data from the literature and following ex‐
tensive discussions within our working group, we recommend ob‐
taining urine for culture according to the child's clinical condition. In 
a febrile child in poor general clinical condition or in a severely ill 
appearing child, urine must be collected by transurethral BC or SPA4 
(grade A). In a febrile child in good clinical condition, a ‘two‐step’ 
approach is feasible5,22; urine can be collected by CVU or bag for 
dipstick.5,11,12,19,21,22,25 If dipstick shows the presence of LE with or 
without nitrites, urine for UC should be collected by CVU or transure‐
thral BC4,11,19,21,25,26 (grade A). If dipstick does not show the presence 
of LE and nitrites, we do not recommend UC but a clinical follow‐up 
and a new dipstick if fever persists after 24‐48 hours (grade B).
2.4 | What is the clinical significance of urine 
dipstick, microscopy and culture?
The sensitivity and specificity of dipstick and microscopy have been 
well summarised in a metanalysis 9 and are reported in Table 2.
Results of the LE test are comparable to those of white blood 
cells by microscopy. Microscopy with Gram staining for bacterial dif‐
ferentiation is the rapid test with the highest sensitivity and specific‐
ity; however, this test is almost never performed in routine settings 
in Italy. While in our previous recommendations the use of dipstick in 
children <2 years of age was discouraged due to its unreliability,1,27 
more recent data in the literature agree on the use of the dipstick 
test also in children <2years.4,28‐31 A practical approach, based on 
the results of LE and nitrite dipstick analysis, is suggested in Table 3.
When urine microscopy is employed, it should be performed on 
a fresh specimen by an expert operator (grade B). Urine culture is 
Method Recommendation References
Bag Not recommended 5,11,19,21
CVU Recommended in primary care
Second choice in hospital settings
(consider micturition stimulating methods in infants 
<6 mo, <10 kg)
11,14‐19,21,23
Transurethral BC First choice in hospital settings and mandatory in 
critically ill children
5,11,19,21,26
SPA Gold standard, but not feasible as a routine procedure 
in primary care
5,11,12,19‐21
Abbreviations: BC, bladder catheterisation; CVU, clean voided urine; SPA, suprapubic aspiration.
TA B L E  1   Urine culture collection 
methods
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required to confirm the diagnosis (grade A): it is considered positive 
if the culture demonstrates the growth of a single organism with a 
colony count threshold which depends on the method used for col‐
lection, as indicated in Table 4 (grade C). However, it is difficult to 
establish a precise cut‐off for interpreting the results of UC, because 
of the heterogeneity and variability of the available literature, as well 
summarised by some authors.10,21 Of course, each result has to be 
evaluated against anamnestic, clinical and laboratory data (fever, 
leucocyturia, bacteremia).10 We give some recommendations on cut‐
offs, keeping in mind that the UC result must be evaluated in the 
context of the clinical situation.
In our settings, where we mainly use CVU samples, we believe 
that both urinary leucocytes and a significant colony count in UC 
(Table 4) are needed for the diagnosis of UTI (grade B).
2.5 | Are blood tests necessary when a UTI is 
suspected?
Routine blood tests are not necessary to identify the site of infec‐
tion. If the child is hospitalised, a complete blood count, C‐reactive 
protein, procalcitonin and renal function tests are indicated (grade 
B), and always recommended in infants <3 months.4,11,32
2.6 | When should a child be hospitalised?
We recommend to hospitalise any critically ill child (sepsis, dehydra‐
tion and vomiting) (grade A), when serious concern of noncompliance 
is present (grade B) and when fever persists after 3 days of appropri‐
ate antibiotic treatment, as shown by sensitivity testing (grade A).33,34
3  | TRE ATMENT
In a febrile child with suggestive clinical signs and/or positive urine 
dipstick or microscopy, antibiotic treatment has to be initiated soon 
after a urine specimen for UC has been obtained. Prompt antibiotic 
treatment is necessary to eradicate the infection, to prevent bacte‐
remia (in particular, during the first months of life) and to improve 
clinical condition (grade A).20,35,36 As regards the risk of UTI‐related 
renal scarring, it is now an established fact the time to initiation of 
antibiotic treatment makes no difference in the frequency and sever‐
ity of scarring, as long as it is initiated within 3‐4 days from the onset 
of fever.35,37‐40 Many studies have demonstrated that starting treat‐
ment either orally or parenterally is of equal effectiveness, and the 
clinician should base their choice of the route of administration on 
practical considerations5,33,34,41‐49: if the UTI is complicated, that is 
TA B L E  2   Sensitivity and specificity of urinary dipstick 
(leucocyte esterase and nitrite) and microscopy (white blood cells 
and bacteria) for diagnosis of urinary tract infection (adapted with 
permission from Williams GJ)9
Test
Sensitivity 
% ( range)
Specificity 
% ( range)
Leucocyte esterase 79 (73‐84) 87 (80‐92)
Nitrite 49 (41‐57) 98 (96‐99)
Leucocyte esterase or nitrite positive 88 (82‐91) 79 (69‐87)
Both leucocyte esterase and nitrite 
positive
45 (30‐61) 98 (96‐99)
Microscopy: white blood cells 74 (67‐80) 86 (82‐90)
Microscopy: unstained bacteria 88 (75‐94) 92 (83‐96)
Microscopy: Gram stain 91 (80‐96) 96 (92‐98)
Nitrite positive
Leucocyte esterase positive UTI very likely
Perform urine culture and start 
antibiotics empirically
Nitrite negative
Leucocyte esterase positive
UTI likely Perform urine culture and start 
antibiotics empirically
Nitrite negative
Leucocyte esterase negative
UTI quite unlikely Search for alternative diagnosis
Abbreviation: UTI, urinary tract infection.
TA B L E  3   Interpretation and suggested 
practical approach following the result 
of nitrite and leucocyte esterase urine 
dipstick
Method
Cut‐off values indicated in the literature
(Reference number)
Our Recommendation
(Grade C)* 
SPA Any growth 11,19,20 or
>50.000 CFU/mL (or less if fever and 
leucocyturia)5
>10.000 CFU/mL
Transurethral BC >50.000 CFU/mL5,10 Or >10.000 CFU/
mL11,19 if fever and leucocyturia 5,10
>10.000 CFU/mL
CVU >100.000 CFU/mL4,11,19‐21 >50.000 CFU/mL
Bag**  >100.000 CFU/mL20,21 >100.000 CFU/mL
Abbreviations: BC, Bladder catheterisation; CVU, clean voided urine; SPA, suprapubic aspiration.
*It refers to children with fever ≥38°C and leucocyturia. 
**Not recommended. 
TA B L E  4   Cut‐off for a significant 
colony count in urine culture according to 
urine collection method
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when the child appears septic or severely dehydrated or is vomiting, 
or if concerns regarding compliance are present, treatment should be 
started parenterally and continued with an oral antibiotic as soon as 
the clinical conditions of the child allow it (grade A); if the UTI is not 
complicated, that is when the febrile child is in good clinical condition 
and able to retain oral fluids and medications and compliance is ex‐
pected, treatment should be administered via the oral route (grade A) 
5,33‐35,46‐49 (Figure 1). The results of oral versus parenteral route do not 
differ in terms of duration of fever, recurrence of UTI or incidence of 
UTI‐related renal scarring.5,11,33,34,42,43
F I G U R E  1   Treatment of urinary tract infection
• < 3 mo
• severely ill
• persisting fever
• low compliance
10 d if pyelonephritis
14 d if urosepsis
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Clinicians should also base their choice of the antibiotic on local 
antimicrobial sensitivity patterns (if available) and adjust it according 
to sensitivity testing of the isolated uropathogen (grade A).5,11,33,34,49 
Escherichia coli remains the predominant uropathogen isolated in 
acute community‐acquired uncomplicated infections (80%), followed 
by Klebsiella, Enterobacter, Proteus species and Enterococci. Many of 
the characteristics of these pathogens are changing, particularly due 
to antimicrobial resistance.50‐56 According to our national pattern of 
resistance,57‐62 we recommend amoxicillin‐clavulanic acid as the first‐
line oral antibiotic and ampicillin‐sulbactam or amoxicillin‐clavulanic 
acid if the intravenous route is indicated (grade B). The increasing re‐
sistance of Escherichia coli to third‐generation cephalosporins (about 
30% in Italy) is mainly due to the widespread and not always appro‐
priate use of this class of antibiotics.62‐64 Therefore, we suggest con‐
sidering cephalosporins (cefixime or ceftibuten for the oral route and 
cefotaxime or ceftriaxone for iv administration) in children with severe 
infections.5,11,33,34,45‐49,62,65,66 In effect cephalosporins have a superior 
efficacy and rapidity of action, making the possible onset of resis‐
tance a less important issue (grade C). Because ceftriaxone is known 
to cause cholestasis,67 it should be used with caution in infants with 
jaundice or those younger than 3 months; cefotaxime should be pre‐
ferred, also due to pharmacokinetic/pharmacodynamic considerations 
and especially because of its renal excretion (grade C).
If UC results show resistance to the prescribed antibiotic but the 
patient's condition is improving, treatment should be continued without 
change (grade C).68,69 In children who are allergic to beta‐lactams, an 
aminoglycoside, such as amikacin or gentamicin, is the best choice (grade 
A), bearing in mind that Pseudomonas Aeruginosa quickly develops anti‐
biotic resistance when aminoglycosides are used as a monotherapy.70,71
Because of the high rate of resistance, the empirical use of tri‐
methoprim must be avoided; it should be used only on the basis of 
antibiogram sensitivity.72
The use of ciprofloxacin in paediatric patients is controversial. 
The use of quinolones should be limited to patients whose clinical 
condition is severe or who are unresponsive to other antibiotics, 
only on the basis of sensitivity patterns, as indicated in recent rec‐
ommendations.73,74 The worrying increase in resistance due to the 
widespread use of quinolones in adults should also be taken into 
consideration.75
Agents that are excreted in the urine but do not achieve therapeutic 
blood concentrations, such as nitrofurantoin, should not be used to treat 
febrile UTIs, because parenchymal and serum antimicrobial concentra‐
tions may be insufficient to treat pyelonephritis or urosepsis (grade A).47
The suggested dosages of the aforementioned antibiotics are 
outlined in Table 5.
There is no consensus in the literature on the optimal duration of 
antimicrobial therapy5,11,33,34,45‐49,76‐78; we suggest a 10‐day course 
for pyelonephritis. For urosepsis, we recommend a 14‐day course to 
be started parenterally; however, parenteral therapy can be limited 
to 3 days in most cases (grade B).
There is insufficient evidence and no recommendations on the 
use of methylprednisolone in the management of acute pyelonephri‐
tis, with one small study showing a significant reduction in scarring 
in the treatment arm that warrants a larger series.48,79
Treatment Dose
Intravenous
Penicillins
Ampicillin‐Sulbactam
Amoxicillin‐clavulanic acid
100 mg/kg/d of ampicillin in 3‐4 doses
100 mg/kg/d of amoxicillin in 3‐4 doses
Cephalosporins
Cefotaxime
Ceftriaxone
150‐200 mg/kg/d in 3‐4 doses* 
75‐100 mg/kg/d in 1 dose* 
Aminoglycosides
Amikacin
Gentamicin
15 mg/kg/d in 1 dose** 
6‐7.5 mg/kg/d in 1 dose** 
Oral route
Amoxicillin‐clavulanic acid 50‐90 mg/kg/d of amoxicillin in 3 doses
Cephalosporins
Cefixime 8 mg/kg twice/d 1st d, once daily thereafter
Ceftibuten 9 mg/kg twice/d 1st d, once daily thereafter
Ciprofloxacin 20‐40 mg/kg/d in 2 doses
Trimethoprim‐sulfamethoxazole 8‐12 mg/kg/d of trimethoprim in 2 doses*** 
Note: Dosages, in accordance with those cited in References (1,35) and with the Sanford Guide to 
Antimicrobial Therapy, may vary from those used in some Institutions or trials. Always compare 
with current product monographs.
*The highest dose in children with urosepsis. 
**Serum levels must be monitored and dosage adjusted accordingly. 
***To be used only on the basis of antibiogram sensitivity, because of the high resistance rate. 
TA B L E  5   Suggested dosage for 
antibiotic treatment of febrile urinary 
tract infections
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4  | IMAGING
4.1 | When and how should ultrasound be 
performed?
We recommend performing RBUS in all children, 2‐4 weeks after the 
first febrile UTI, in order to detect renal and urinary tract anomalies 
(grade B). We do not recommend a RBUS during the febrile UTI, unless 
it is complicated, atypical or severe (presence of any of the follow‐
ing: septic state, fever persisting after 3 days of appropriate antibiotic 
treatment, elevated plasma creatinine, oliguria)(grade B).49
The RBUS report should always describe the characteristics 
of the kidneys, and in particular renal length, echogenicity and 
thickness of the parenchyma. Other important characteristics are 
the features of the calices, the antero‐posterior diameter of the 
renal pelvis at the exit from the renal parenchyma, the maximum 
diameter of the ureter, the wall thickness of the bladder and, if 
possible, pre‐ and post‐void bladder volume. We also recommend 
that the presence or absence of renal pelvic uroepithelial thicken‐
ing is reported.
It is, however, important to point out that a great deal of evidence 
exists on the low predictive value of renal ultrasound as regards the 
presence of VUR. This examination is frequently normal in children 
with low‐grade, and even in some with high‐grade, VUR, and while 
mild and transient renal pelvic or ureteral distension is common, it is 
often not associated with VUR. On the other hand, abnormal RBUS 
findings represent a risk factor for UTI‐related renal scarring and are 
present in up to 86% of patients with high‐grade VUR.80 Among the 
abnormal findings, of particular relevance are as follows: mono‐ or 
bilateral renal hypoplasia, major pelvi‐calyceal dilatation, ureteral 
dilatation and uroepithelial thickening of the renal pelvis.81
4.2 | When and how should imaging to detect VUR 
be performed?
We recommend imaging in order to detect VUR after the first febrile 
UTI when RBUS reveals mono‐ or bilateral renal hypoplasia, anoma‐
lies of parenchymal echogenicity, ureteral dilatation, uroepithelial 
thickening of the renal pelvis and pelvi‐calyceal dilatation, particu‐
larly if associated with uroepithelial thickening, bladder abnormali‐
ties (grade B). An isolated dilatation of the renal pelvis generally does 
not represent an indication for further imaging (grade B). In addition, 
imaging for the detection of VUR should be performed when the UTI 
is caused by a pathogen other than Escherichia coli (grade A)2,82 and 
in children with recurrent febrile UTIs (Figure 2).
4.2.1 | Imaging options
Currently, there are four imaging modalities available for the detec‐
tion of VUR.
Fluoroscopic contrast voiding cystourethrography (VCUG) is the 
standard method for the diagnosis of VUR, the assessment of the 
degree of reflux and the anatomy of the male urethra (grade A). A 
standardised protocol for VCUG performance has recently been is‐
sued: in boys, lidocaine gel is instilled in the urethra before catheter‐
isation; a small age‐appropriate (3.5‐8 French) non‐balloon catheter 
is inserted by means of a sterile procedure; the bladder should be 
filled until voiding occurs and if VUR is not identified on the first 
void, a second filling with the same catheter should be performed to 
increase the chance for detection of VUR.83
Vesico‐ureteric reflux is detected with equal or superior sensi‐
tivity by direct radionuclide cystography, which delivers much less 
radiation than VCUG, but is less readily available and does not pro‐
vide anatomic details of the male urethra; it could represent the first 
choice in females (grade B).
Contrast enhanced voiding ultrasonography is a sensitive mo‐
dality used to detect VUR84,85; in addition, a second‐generation 
contrast agent and a transperineal approach enables a precise eval‐
uation of the bladder and male urethra.86 It is less commonly per‐
formed because it is time consuming, expensive and not available 
on a large scale.
The last option is indirect radioisotopic cystography, which can 
be obtained during the last phases of a MAG 3 scintigraphy; how‐
ever, it has a low sensitivity and specificity.
4.3 | Is antibiotic treatment necessary at the time of 
catheter insertion for imaging?
Even though it is widely prescribed in clinical practice, prescription of 
antibiotic therapy is debated: some guidelines recommend its use,11 
but recent data show that the risk of UTI after VCUG is very low.87 
We suggest administering antibiotic treatment at full dosage for three 
days in infants, especially within the first 12 months of life, or when 
major urinary tract abnormalities are present at RBUS (grade C).
4.4 | Scintigraphy
Scintigraphy is not routinely recommended after the first UTI. The 
implementation of a renal cortical scintigraphy (with DMSA) is rec‐
ommended in all children with VUR grades IV and V, which have 
been recognised as major risk factors for permanent renal damage 
(grade B).88,89 In order to evaluate the presence of UTI‐related renal 
scarring, a renal scan has to be performed at least 6 months after the 
febrile UTI, the time required to avoid misinterpretation of transient 
changes related to the acute infection.
5  | WHAT TO DO AF TER THE FIRST 
FEBRILE UTI?
Most febrile UTIs in children are uneventful infections, occurring in 
otherwise normal children who have an excellent prognosis. A rela‐
tively small number of children (6%‐10%) will develop recurrences, 
generally during the following year.46 Recurrence risk factors are 
high‐grade reflux, age below 1 year in males, female sex and bladder 
bowel dysfunction.
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Generally speaking, it is important to instruct parents to rec‐
ognise UTI symptoms and to prevent modifiable risk factors for 
recurrent UTIs and in particular constipation and bladder bowel dys‐
function.90,91 We believe that also a low fluid intake has to be taken 
into consideration (grade C).
Circumcision is a conceivable option in selected cases of males 
with high‐grade VUR and with recurrent febrile UTIs despite other 
efforts to prevent infections.
As regards antibiotic prophylaxis, it has been used for decades 
in children with VUR, with the assumption that renal damage and 
its progression would be prevented if recurrent UTIs were avoided. 
Currently, its effectiveness is under debate. A number of recent ran‐
domized controlled trials have shown no or a minimal effect of an‐
tibiotic prophylaxis in reducing the recurrence of UTIs.92‐96 Various 
meta‐analyses have been published 97‐99; among those, the one pub‐
lished by De Bessa et al99appears of particular interest, as the au‐
thors separated dilating (grades III‐IV‐V) and non‐dilating (grades I‐II) 
VUR as far as breakthrough infections are concerned. Analysing the 
first published studies, the authors found that antibiotic prophylaxis 
would be beneficial only in children with high‐grade VUR. With the 
addition of the data from the RIVUR study,100 these results changed, 
supporting antibiotic prophylaxis in all children with VUR. It has 
to be underlined that the RIVUR trial evaluated 607 children (92% 
female) with an age range of 2‐71 months, 126 were toilet trained, 
71 of them had bladder bowel dysfunction, and 92% had grade I to 
III reflux. We believe that the treatment showed statistical, but not 
clinical significance: 22 patient‐years of antibiotics were required to 
prevent one febrile UTI. Therefore, the analysis of the data regarding 
recurrent infections does not stand in favour of the use of antibiotic 
prophylaxis, at least in children with low‐grade reflux.
An additional concern is the propensity of antibiotics to induce 
bacterial resistance. A recent meta‐analysis by Selekman et al101 
showed that prophylaxis increases the risk of multidrug resistance 
(children receiving prophylaxis had 6.4 times the odds), with im‐
portant implications in the risk‐benefit assessment of prophylaxis.
Concurrently, it has become clear that prophylaxis does not reduce 
the appearance and progression of permanent renal damage, as shown 
by multiple recent meta‐analyses.97‐99,102 Furthermore, the treatment 
group from the RIVUR trial received together over 600 years of pro‐
phylaxis, without a demonstrable effect on scar formation.
In conclusion, antibiotic prophylaxis is not routinely recom‐
mended in infants and children after the first febrile UTI (grade A). 
It may be considered in infants and children after treatment of the 
acute episode until VCUG is performed (grade C), with reflux grades 
IV and V (grade C), and with recurrent febrile UTIs, defined as >3 
febrile UTIs within 12 months (grade C).
These recommendations are in line with the main international 
guidelines.4,5,11
As a first choice prophylactic agent, we suggest amoxicillin‐clavulanic 
acid, while ceftibuten or nitrofurantoin should be regarded as secondary 
options, keeping in mind that nitrofurantoin may cause gastrointestinal 
intolerance and is inactive against most strains of Proteus.103 There is 
insufficient evidence to recommend a specific dose; however, tradition‐
ally, the dose used for prophylaxis has been one‐quarter to one‐third 
of the treatment dose, given once per day. There are no data on the 
efficacy of the practice of alternating prophylactic antibiotics.
Similarly, the optimal duration of prophylaxis has not been es‐
tablished. According to the longer susceptibility to UTI in girls than 
in boys, we suggest 12‐24 months in girls and 6‐12 months in boys 
(grade C).
F I G U R E  2   When should imaging 
to detect vesicoureteral reflux be 
performed? Legends: SFU, Society for 
foetal Urology; VCUG, fluoroscopic 
contrast voiding cystourethrography; 
RNC, direct radionuclide cystography; 
CEVUS, contrast enhanced voiding 
ultrasonography
First febrile urinary tract infection
At least one of the following 
ultrasound abnormalities:
• Unilateral or bilateral renal hypoplasia
• Abnormal renal echogenicity
• Pelvi-caliceal dilatation (≥2°SFU grade 
hydronephrosis)
• Ureteral dilatation 
• Uroepithelial thickening of the renal 
pelvis
• Bladder abnormalities (ureterocele, 
diverticulum)
Pathogen other 
than E. coli
and/or
VCUG or RNC or CEVUS
Second febrile UTI
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5.1 | Other interventions for preventing UTI
Several interventions, other than antibiotic prophylaxis, have been 
used for the prevention of recurrent UTIs, but evidence for their ef‐
fectiveness in infants and children is lacking.104
The efficacy of cranberry juice remains questionable. In a study 
on children aged 1‐6 years, with recurrent UTIs, but no or minor uro‐
logic malformations, the intervention (cranberry for 6 months) did 
not significantly reduce the number of children who experienced a 
recurrence of UTI, but it was effective in reducing the actual number 
of recurrences and related antimicrobial use.105
Few studies are available on probiotics and, at present, no signif‐
icant benefit has been demonstrated for UTI prevention.106
6  | HE ALTH BENEFITS ,  POTENTIAL 
RISKS AND LIMITATIONS OF OUR 
RECOMMENDATIONS
Our recommendations are useful in helping the practicing clinician to de‐
termine the diagnostic and therapeutic approach to a child with a febrile 
UTI. Furthermore, the clinical use of the recommendations will lead to a 
reduction in the number of performed VCUG, and therefore to a reduction 
of radiation and financial costs. On the other hand, reducing the number 
of VCUG could produce the risk of missing a small number of high‐grade 
VUR after the first febrile UTI; anyhow, a second febrile UTI represents in 
our recommendation an indication to further imaging. Another health ben‐
efit may be represented by a more restricted use of antibiotic prophylaxis, 
also addressing the problem of growing antibiotic resistance; of course, 
the risk of increasing UTI recurrences has to be kept in mind.
7  | FUTURE RESE ARCH
The authors of these recommendations have found some gaps in the 
knowledge on UTI in infants and children, needing further studies. In 
particular, we suggest the need to study the number of colony count 
needed to make a diagnosis of UTI and the scientific rationale to recom‐
mend different numbers of colony counts for different urine collection 
modalities. Other points are the meaning of nitrites in the absence of 
leucocyturia, the role of steroids in preventing the appearance of scar‐
ring, the role of a high fluid intake in preventing recurrent infections 
and the need of antibiotic prophylaxis in children with high‐grade reflux.
Further research should also establish if a shorter duration of anti‐
biotic treatment is warranted. Most importantly, needed to establish 
the potential morbidity of UTIs in the long‐term,107 are prospective 
studies following a first febrile UTI in children with normal kidneys as 
well as in children with prenatally diagnosed hypodysplasia.
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UTI recommendations at a glance
Diagnosis. The diagnosis of UTI should be considered in chil‐
dren presenting with fever (38°C or higher) and no apparent 
source. Urine should be collected and analysed by micros‐
copy or dipstick to identify children in whom UTI is very likely 
(leucocyturia with or without nitrites) and by urine culture to 
make a definitive diagnosis.
Urine culture. To collect urine, a two‐step approach is feasi‐
ble in febrile children in good clinical condition. Urine can be 
collected by clean voided method or bag for dipstick. If the 
dipstick shows the presence of leucocytes with or without ni‐
trites, a sample for urine culture should be collected by clean 
voided urine or transurethral bladder catheterisation. If the 
dipstick is normal, there is no need to perform a urine cul‐
ture and a new dipstick is recommended after 24‐48 h, if the 
fever persists. In a severely ill febrile child urine must be col‐
lected by transurethral bladder catheterisation or suprapubic 
aspiration.
Treatment. In a febrile child with positive urine dipstick or 
microscopy, antibiotic treatment must be initiated soon after 
urine culture is obtained. Suggested antibiotics are as follows: 
amoxicillin‐clavulanic acid as first line if the oral route is pos‐
sible in children who appear well and ampicillin‐sulbactam or 
amoxicillin‐clavulanic acid if the intravenous route is indicated 
in severely ill children.
Imaging. A renal and bladder ultrasound is suggested in all 
children, 2‐4 wk after the febrile UTI, while voiding cystoure‐
thrography is indicated when ultrasound reveals major anom‐
alies of the kidney and/or urinary tract and/or when the UTI is 
caused by a pathogen other than Escherichia coli.
Antibiotic prophylaxis. This is not routinely recommended 
after the first febrile UTI. It may be considered in children with 
reflux grade IV and V, or with recurrent febrile UTIs, defined 
as more than three febrile UTIs within 12 mo.
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